Pacific Biosciences of California (PACB) to Release Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $40.68 million for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Pacific Biosciences of California Stock Down 2.5 %

Shares of NASDAQ PACB traded down $0.04 during trading hours on Friday, hitting $1.56. The company had a trading volume of 6,879,259 shares, compared to its average volume of 10,437,161. The stock has a market capitalization of $427.22 million, a P/E ratio of -1.07 and a beta of 1.92. Pacific Biosciences of California has a 1-year low of $1.16 and a 1-year high of $6.83. The firm's 50 day moving average is $1.85 and its 200-day moving average is $1.81. The company has a quick ratio of 8.64, a current ratio of 9.74 and a debt-to-equity ratio of 1.97.

Insider Activity

In other Pacific Biosciences of California news, insider Oene Mark Van sold 34,405 shares of Pacific Biosciences of California stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $2.03, for a total value of $69,842.15. Following the completion of the sale, the insider now owns 1,597,454 shares in the company, valued at $3,242,831.62. The trade was a 2.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. The Goldman Sachs Group decreased their price objective on shares of Pacific Biosciences of California from $2.25 to $1.75 and set a "neutral" rating for the company in a research report on Thursday, January 23rd. Piper Sandler lifted their price target on Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a "neutral" rating in a report on Monday, November 11th. StockNews.com raised Pacific Biosciences of California to a "sell" rating in a research report on Thursday, January 9th. Scotiabank cut their price objective on Pacific Biosciences of California from $7.00 to $6.00 and set a "sector outperform" rating for the company in a research report on Monday, November 11th. Finally, UBS Group lowered Pacific Biosciences of California from a "buy" rating to a "neutral" rating and set a $2.00 target price on the stock. in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Pacific Biosciences of California presently has a consensus rating of "Hold" and an average target price of $2.89.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.